NCT02117570 - A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine. | Biotech Hunter

Enrollment

185

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Clostridium Difficile Associated Disease

Interventions

BIOLOGICAL

Clostridium difficile vaccine

0.5 mL intramuscular injection on day 1, day 8, and day 30.

BIOLOGICAL

Clostridium difficile vaccine

0.5 mL intramuscular injection on day 1, day 8, and day 30.

BIOLOGICAL

Placebo

Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.

Trial Locations (12)

PMG Research of Winston-Salem, Winston-Salem

PMG Research of Charlotte, Charlotte

PMG Research of Wilmington, LLC, Wilmington

Clinical Research Atlanta, Stockbridge

Meridian Clinical Research, Savannah

Avail Clinical Research, LLC, DeLand

Meridian Clinical Research, LLC, Omaha

Meridian Clinical Research, Norfolk

Benchmark Research, San Angelo

Clinical Trials of Texas, Inc., San Antonio

Benchmark Research, Austin

Clinical Research Center of Nevada, LLC, Las Vegas